MD3411381T2 - Triterpenoide modificate C-3 și C-17 în calitate de inhibitori ai HIV-1 - Google Patents

Triterpenoide modificate C-3 și C-17 în calitate de inhibitori ai HIV-1 Download PDF

Info

Publication number
MD3411381T2
MD3411381T2 MDE20181181T MDE20181181T MD3411381T2 MD 3411381 T2 MD3411381 T2 MD 3411381T2 MD E20181181 T MDE20181181 T MD E20181181T MD E20181181 T MDE20181181 T MD E20181181T MD 3411381 T2 MD3411381 T2 MD 3411381T2
Authority
MD
Moldova
Prior art keywords
alkyl
group
substituted
heteroaryl
cycloalkyl
Prior art date
Application number
MDE20181181T
Other languages
English (en)
Romanian (ro)
Inventor
Jie Chen
Yan Chen
Ira B Dicker
Richard A Hartz
Nicholas A Meanwell
Alicia Regueiro-Ren
Sing-Yuen Sit
Ny Sin
Jacob Swidorski
Brian Lee Venables
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MD3411381T2 publication Critical patent/MD3411381T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/52Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MDE20181181T 2016-02-04 2017-02-02 Triterpenoide modificate C-3 și C-17 în calitate de inhibitori ai HIV-1 MD3411381T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (1)

Publication Number Publication Date
MD3411381T2 true MD3411381T2 (ro) 2021-07-31

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20181181T MD3411381T2 (ro) 2016-02-04 2017-02-02 Triterpenoide modificate C-3 și C-17 în calitate de inhibitori ai HIV-1

Country Status (39)

Country Link
US (4) US10421774B2 (enExample)
EP (2) EP3831839B1 (enExample)
JP (1) JP6735837B2 (enExample)
KR (1) KR102795662B1 (enExample)
CN (1) CN109153700B (enExample)
AR (1) AR107512A1 (enExample)
AU (1) AU2017215529B2 (enExample)
BR (1) BR112018015629B1 (enExample)
CA (1) CA3013417C (enExample)
CL (1) CL2018002084A1 (enExample)
CO (1) CO2018008157A2 (enExample)
CR (1) CR20180387A (enExample)
CY (1) CY1124353T1 (enExample)
DK (1) DK3411381T3 (enExample)
DO (1) DOP2018000174A (enExample)
EA (1) EA036211B1 (enExample)
ES (2) ES2957767T3 (enExample)
HR (1) HRP20210502T1 (enExample)
HU (1) HUE054337T2 (enExample)
IL (1) IL260741B (enExample)
JO (1) JOP20170029B1 (enExample)
LT (1) LT3411381T (enExample)
MA (2) MA53358A (enExample)
MD (1) MD3411381T2 (enExample)
MX (1) MX375118B (enExample)
MY (1) MY199668A (enExample)
PE (1) PE20181355A1 (enExample)
PL (1) PL3411381T3 (enExample)
PT (1) PT3411381T (enExample)
RS (1) RS61746B1 (enExample)
RU (1) RU2716502C2 (enExample)
SG (1) SG11201806388XA (enExample)
SI (1) SI3411381T1 (enExample)
SM (1) SMT202100210T1 (enExample)
TW (1) TWI719126B (enExample)
UA (1) UA123867C2 (enExample)
UY (1) UY37109A (enExample)
WO (1) WO2017134596A1 (enExample)
ZA (1) ZA201805044B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
MX2022006940A (es) 2019-12-09 2022-07-11 Viiv Healthcare Co Composiciones farmaceuticas.
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
MX2012013628A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
CN103038245B (zh) 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
RS54352B1 (sr) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
ES2584684T3 (es) * 2011-12-14 2016-09-28 Glaxosmithkline Llc Derivados de propenoato de betulina
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
MX2015010354A (es) * 2013-02-25 2015-10-09 Squibb Bristol Myers Co Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
PL3129392T3 (pl) * 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
DK3984994T3 (da) 2016-02-04 2024-10-14 Takeda Pharmaceuticals Co Substitueret piperidinforbindelse som orexin-type 2-agonist til behandling af narkolepsi

Also Published As

Publication number Publication date
CA3013417C (en) 2024-01-02
HK1256866A1 (en) 2019-10-04
SI3411381T1 (sl) 2021-04-30
AU2017215529A8 (en) 2018-08-30
HRP20210502T1 (hr) 2021-05-14
NZ744545A (en) 2025-03-28
RU2716502C2 (ru) 2020-03-12
WO2017134596A1 (en) 2017-08-10
AU2017215529A1 (en) 2018-08-23
JP6735837B2 (ja) 2020-08-05
RU2018130181A3 (enExample) 2020-03-05
MA43960A (fr) 2018-12-12
CN109153700A (zh) 2019-01-04
PE20181355A1 (es) 2018-08-22
EP3831839B1 (en) 2023-07-26
SG11201806388XA (en) 2018-08-30
HUE054337T2 (hu) 2021-08-30
CR20180387A (es) 2018-09-20
EP3831839A3 (en) 2021-07-21
BR112018015629A2 (pt) 2018-12-26
US20190031709A1 (en) 2019-01-31
DK3411381T3 (da) 2021-04-06
EA201891649A1 (ru) 2019-02-28
CN109153700B (zh) 2021-03-09
EP3411381B1 (en) 2021-01-20
CA3013417A1 (en) 2017-08-10
US11084845B2 (en) 2021-08-10
US20210323997A1 (en) 2021-10-21
AU2017215529B2 (en) 2019-01-31
UY37109A (es) 2017-09-29
AR107512A1 (es) 2018-05-09
PT3411381T (pt) 2021-03-18
UA123867C2 (uk) 2021-06-16
CL2018002084A1 (es) 2018-09-21
ES2957767T3 (es) 2024-01-25
US10421774B2 (en) 2019-09-24
RS61746B1 (sr) 2021-05-31
MX2018009514A (es) 2018-09-05
DOP2018000174A (es) 2018-10-31
MA53358A (fr) 2021-07-21
KR102795662B1 (ko) 2025-04-14
MY199668A (en) 2023-11-15
SMT202100210T1 (it) 2021-05-07
LT3411381T (lt) 2021-04-26
CY1124353T1 (el) 2022-07-22
EP3831839A2 (en) 2021-06-09
KR20180105229A (ko) 2018-09-27
JOP20170029B1 (ar) 2021-08-17
US20190359647A1 (en) 2019-11-28
PL3411381T3 (pl) 2021-09-13
RU2018130181A (ru) 2020-03-05
US20230295220A1 (en) 2023-09-21
CO2018008157A2 (es) 2018-08-21
EP3411381A1 (en) 2018-12-12
ZA201805044B (en) 2020-08-26
EA036211B1 (ru) 2020-10-14
ES2862325T3 (es) 2021-10-07
MX375118B (es) 2025-03-06
TWI719126B (zh) 2021-02-21
IL260741B (en) 2020-04-30
TW201739757A (zh) 2017-11-16
BR112018015629B1 (pt) 2023-10-24
JP2019504104A (ja) 2019-02-14
MA43960B1 (fr) 2021-02-26

Similar Documents

Publication Publication Date Title
MD3411381T2 (ro) Triterpenoide modificate C-3 și C-17 în calitate de inhibitori ai HIV-1
JP5752789B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
KR20140123584A (ko) Hiv 성숙 억제 활성을 갖는 c-3 시클로알케닐 트리테르페노이드
JP6100786B2 (ja) 抗ウイルス活性を有する新規ベツリン酸誘導体
JP5755731B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド
KR20150115881A (ko) Hiv 성숙 억제 활성을 갖는 c-19 변형된 트리테르페노이드
KR20160147809A (ko) 할로알킬 치환기를 지니는 비­방향족 고리에 의해 위치 3에서 치환된,hiv 성숙화 억제 활성을 갖는 트리테르페노이드
AU2015346303B2 (en) Oxolupene derivatives
WO2015195776A1 (en) Betulinic acid derivatives with hiv maturation inhibitory activity
JP6620149B2 (ja) 拡張ベツリン酸類似体
JP2017533934A (ja) C17アリール置換ベツリン酸類似体